Recent advances in the treatment of hypertension

References

• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet365(9455), 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• WHO. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. WHO Press, Geneva, Switzerland (2009).
   Google Scholar
• Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med.342(13), 905–912 (2000).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25(6), 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Perkovic V, Huxley R, Wu Y, Prabhakaran D, Macmahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension50(6), 991–997 (2007).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J. Hypertens.22(1), 11–19 (2004).
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA290(2), 199–206 (2003).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension51(6), 1403–1419 (2008).
   PubMed Web of Science ®Google Scholar
• Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J. Clin. Hypertens. (Greenwich)4(6), 393–404 (2002).
   PubMedGoogle Scholar
• Pimenta E, Gaddam KK, Oparil S et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension54(3), 475–481 (2009).
   PubMed Web of Science ®Google Scholar
• Graudal NA, Galloe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA279(17), 1383–1391 (1998).
   PubMed Web of Science ®Google Scholar
• Ekinci EI, Clarke S, Thomas MC et al. Dietary salt intake and mortality in patients with Type 2 diabetes. Diabetes Care34(3), 703–709 (2011).
   PubMed Web of Science ®Google Scholar
• Thomas MC, Moran J, Forsblom C et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with Type 1 diabetes. Diabetes Care34(4), 861–866 (2011).
   PubMed Web of Science ®Google Scholar
• Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin. Sci. (Lond.)114(3), 221–230 (2008).
   PubMed Web of Science ®Google Scholar
• Huang Z, Willett WC, Manson JE et al. Body weight, weight change, and risk for hypertension in women. Ann. Intern. Med.128(2), 81–88 (1998).
   PubMed Web of Science ®Google Scholar
• Cocco G, Pandolfi S. Physical exercise with weight reduction lowers blood pressure and improves abnormal left ventricular relaxation in pharmacologically treated hypertensive patients. J. Clin. Hypertens. (Greenwich)13(1), 23–29 (2011).
   PubMed Web of Science ®Google Scholar
• Straznicky NE, Grima MT, Eikelis N et al. The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J. Clin. Endocrinol. Metab.96(3), E503–E508 (2011).
   PubMed Web of Science ®Google Scholar
• Daniels SR, Kimball TR, Khoury P, Witt S, Morrison JA. Correlates of the hemodynamic determinants of blood pressure. Hypertension28(1), 37–41 (1996).
   PubMed Web of Science ®Google Scholar
• Stamler J. Epidemiologic findings on body mass and blood pressure in adults. Ann. Epidemiol.1(4), 347–362 (1991).
   PubMedGoogle Scholar
• Haynes RB, Mcdonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA288(22), 2880–2883 (2002).
   PubMed Web of Science ®Google Scholar
• Straznicky N, Grassi G, Esler M et al. European Society of Hypertension Working Group on obesity antihypertensive effects of weight loss: myth or reality? J. Hypertens.28(4), 637–643 (2010).
   PubMed Web of Science ®Google Scholar
• Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA292(14), 1724–1737 (2004).
   PubMed Web of Science ®Google Scholar
• Maggard MA, Shugarman LR, Suttorp M et al. Meta-analysis: surgical treatment of obesity. Ann. Intern. Med.142(7), 547–559 (2005).
   PubMed Web of Science ®Google Scholar
• Sjostrom CD, Peltonen M, Sjostrom L. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes. Res.9(3), 188–195 (2001).
   PubMedGoogle Scholar
• Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann. Surg.237(6), 751–756; discussion 757–758 (2003).
   PubMed Web of Science ®Google Scholar
• Adami G, Murelli F, Carlini F, Papadia F, Scopinaro N. Long-term effect of biliopancreatic diversion on blood pressure in hypertensive obese patients. Am. J. Hypertens.18(6), 780–784 (2005).
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernandez JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension51(1), 69–76 (2008).
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojon A, Fernandez JR. Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. Am. J. Hypertens.23(4), 432–439 (2010).
   PubMed Web of Science ®Google Scholar
• Matos JP, de Lourdes Rodrigues M, Ismerim VL, Boasquevisque EM, Genelhu V, Francischetti EA. Effects of dual blockade of the renin angiotensin system in hypertensive Type 2 diabetic patients with nephropathy. Clin. Nephrol.64(3), 180–189 (2005).
   PubMed Web of Science ®Google Scholar
• Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med.148(1), 30–48 (2008).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358(15), 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Tobe SW, Clase CM, Gao P et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation123(10), 1098–1107 (2011).
   PubMed Web of Science ®Google Scholar
• Mcalister FA, Zhang J, Tonelli M, Klarenbach S, Manns BJ, Hemmelgarn BR. The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis. CMAJ183(6), 655–662 (2011).
   PubMed Web of Science ®Google Scholar
• Maione A, Navaneethan SD, Graziano G et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol. Dial. Transplant. DOI: 10.1093/ndt/gfq792 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension39(1), E1–E8 (2002).
   PubMed Web of Science ®Google Scholar
• Stanton A, Jensen C, Nussberger J, O’brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension42(6), 1137–1143 (2003).
   PubMed Web of Science ®Google Scholar
• Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation111(8), 1012–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J. Hum. Hypertens.24(9), 600–608 (2010).
   PubMed Web of Science ®Google Scholar
• Solomon SD, Appelbaum E, Manning WJ et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation119(4), 530–537 (2009).
   PubMed Web of Science ®Google Scholar
• Solomon SD, Hee Shin S, Shah A et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur. Heart J.32(10), 1227–1234 (2011).
   PubMed Web of Science ®Google Scholar
• Seed A, Gardner R, Mcmurray J et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur. J. Heart Fail.9(11), 1120–1127 (2007).
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med.358(23), 2433–2446 (2008).
   PubMed Web of Science ®Google Scholar
• Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with Type 2 diabetes and nephropathy. Clin. J. Am. Soc. Nephrol.6(5), 1025–1031 (2011).
   PubMed Web of Science ®Google Scholar
• Brown MJ, Mcinnes GT, Papst CC, Zhang J, Macdonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet377(9762), 312–320 (2011).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359(23), 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med.341(10), 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension49(4), 839–845 (2007).
   PubMed Web of Science ®Google Scholar
• De Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension55(1), 147–152 (2010).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J. Am. Soc. Hypertens.2(6), 462–468 (2008).
   PubMed Web of Science ®Google Scholar
• Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am. J. Kidney Dis.37(4), 699–705 (2001).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension40(6), 892–896 (2002).
   PubMed Web of Science ®Google Scholar
• Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J. Hum. Hypertens.17(5), 349–352 (2003).
   PubMed Web of Science ®Google Scholar
• Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J. Hypertens.22(11), 2217–2226 (2004).
   PubMed Web of Science ®Google Scholar
• Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension50(3), 447–453; discussion 447–453 (2007).
   PubMed Web of Science ®Google Scholar
• Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet371(9628), 1921–1926 (2008).
   PubMed Web of Science ®Google Scholar
• Fiebeler A, Nussberger J, Shagdarsuren E et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation111(23), 3087–3094 (2005).
   PubMed Web of Science ®Google Scholar
• Menard J, Gonzalez MF, Guyene TT, Bissery A. Investigation of aldosterone-synthase inhibition in rats. J. Hypertens.24(6), 1147–1155 (2006).
   PubMed Web of Science ®Google Scholar
• Huang BS, White RA, Ahmad M, Jeng AY, Leenen FH. Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats. Am. J. Physiol. Regul. Integr. Comp. Physiol.295(1), R166–R172 (2008).
   Google Scholar
• Mulder P, Mellin V, Favre J et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur. Heart J.29(17), 2171–2179 (2008).
   PubMed Web of Science ®Google Scholar
• Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am. J. Hypertens.17(2), 103–111 (2004).
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet375(9722), 1255–1266 (2010).
   PubMed Web of Science ®Google Scholar
• Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelin. A receptor antagonist for treatment of hypertension. Am. J. Hypertens.15(7 Pt 1), 583–589 (2002).
   PubMed Web of Science ®Google Scholar
• Black HR, Bakris GL, Weber MA et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J. Clin. Hypertens. (Greenwich)9(10), 760–769 (2007).
   PubMedGoogle Scholar
• Weber MA, Black H, Bakris G et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet374(9699), 1423–1431 (2009).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Lindholm LH, Black HR et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension56(5), 824–830 (2010).
   PubMed Web of Science ®Google Scholar
• Raichlin E, Prasad A, Mathew V et al. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension52(3), 522–528 (2008).
   PubMed Web of Science ®Google Scholar
• Kohan DE, Pritchett Y, Molitch M et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J. Am. Soc. Nephrol.22(4), 763–772 (2011).
   PubMed Web of Science ®Google Scholar
• Nieto FJ, Young TB, Lind BK et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA283(14), 1829–1836 (2000).
   PubMed Web of Science ®Google Scholar
• Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N. Engl. J. Med.342(19), 1378–1384 (2000).
   PubMed Web of Science ®Google Scholar
• Logan AG, Tkacova R, Perlikowski SM et al. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur. Respir. J.21(2), 241–247 (2003).
   PubMed Web of Science ®Google Scholar
• Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am. J. Respir. Crit. Care Med.176(7), 706–712 (2007).
   PubMed Web of Science ®Google Scholar
• Campos-Rodriguez F, Grilo-Reina A, Perez-Ronchel J et al. Effect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial. Chest129(6), 1459–1467 (2006).
   PubMed Web of Science ®Google Scholar
• Becker HF, Jerrentrup A, Ploch T et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation107(1), 68–73 (2003).
   PubMed Web of Science ®Google Scholar
• Drager LF, Pedrosa RP, Diniz PM et al. The effects of continuous positive airway pressure on prehypertension and masked hypertension in men with severe obstructive sleep apnea. Hypertension57(3), 549–555 (2011).
   PubMed Web of Science ®Google Scholar
• Lohmeier TE, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension43(2), 306–311 (2004).
   PubMed Web of Science ®Google Scholar
• Illig KA, Levy M, Sanchez L et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter Phase II Rheos feasibility trial. J. Vasc. Surg.44(6), 1213–1218 (2006).
   PubMed Web of Science ®Google Scholar
• Lovett EG, Schafer J, Kaufman CL. Chronic baroreflex activation by the Rheos System: an overview of results from european and North American feasibility studies. Conf. Proc. IEEE Eng. Med. Biol. Soc.4626–4630 (2009).
   Google Scholar
• Sanchez LA, Illig K, Levy M et al. Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology. Ann. Vasc. Surg.24(2), 178–184 (2010).
   PubMed Web of Science ®Google Scholar
• Krum H, Schlaich M, Sobotka P, Scheffers I, Kroon AA, De Leeuw PW. Novel procedure- and device-based strategies in the management of systemic hypertension. Eur. Heart J.32(5), 537–544 (2011).
   PubMed Web of Science ®Google Scholar
• Heusser K, Tank J, Engeli S et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension55(3), 619–626 (2010).
   PubMed Web of Science ®Google Scholar
• Young KC, Teeters JC, Benesch CG, Bisognano JD, Illig KA. Cost–effectiveness of treating resistant hypertension with an implantable carotid body stimulator. J. Clin. Hypertens. (Greenwich)11(10), 555–563 (2009).
   PubMed Web of Science ®Google Scholar
• Campese VM. Neurogenic factors and hypertension in chronic renal failure. J. Nephrol.10(4), 184–187 (1997).
   PubMed Web of Science ®Google Scholar
• Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J. Am. Med. Assoc.152(16), 1501–1504 (1953).
   PubMed Web of Science ®Google Scholar
• Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet1(6757), 403–408 (1953).
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension54(6), 1195–1201 (2009).
   PubMed Web of Science ®Google Scholar
• Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet373(9671), 1275–1281 (2009).
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Engl. J. Med.361(9), 932–934 (2009).
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Krum H, Sobotka PA, Esler MD. Renal denervation and hypertension. Am. J. Hypertens.24(6), 635–642(2011).
   PubMed Web of Science ®Google Scholar
• Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension57(5), 911–917 (2011).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int.50(5), 1641–1650 (1996).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis.36(3), 646–661 (2000).
   PubMed Web of Science ®Google Scholar
• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet376(9756), 1903–1909 (2010).
   PubMed Web of Science ®Google Scholar
• Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP. Sympathetic nervous activation in obesity and the metabolic syndrome – causes, consequences and therapeutic implications. Pharmacol. Ther.126(2), 159–172 (2010).
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Schlaich M, Kindermann I et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study Circulation123(1), 1940–1946 (2011).
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Straznicky N, Grima M et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J. Hypertens.29(5), 991–996 (2011).
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Socratous F, Hennebry S et al. Sympathetic activation in chronic renal failure. J. Am. Soc. Nephrol.20(5), 933–939 (2009).
   PubMed Web of Science ®Google Scholar
• Straznicky NE, Grima MT, Lambert EA et al. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J. Hypertens.29(3), 553–564 (2011).
   PubMed Web of Science ®Google Scholar